Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin and Pentoxifylline in CKD
NCT06458465Completed
- Sponsor
- Alexandria University
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of curcumin and pentoxifylline in chronic kidney disease (CKD) (3 arms), sponsored by Alexandria University. Primary endpoints: Change in p-cresyl sulfate at 6 months, Change in high sensitive C-reactive protein at 6 months and 5 more. Started Oct 2023; status: completed.
02
Drugs
curcuminpentoxifylline
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06458465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06458465.